Nature Communications (May 2016)
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
- Jan A. Burger,
- Dan A. Landau,
- Amaro Taylor-Weiner,
- Ivana Bozic,
- Huidan Zhang,
- Kristopher Sarosiek,
- Lili Wang,
- Chip Stewart,
- Jean Fan,
- Julia Hoellenriegel,
- Mariela Sivina,
- Adrian M. Dubuc,
- Cameron Fraser,
- Yulong Han,
- Shuqiang Li,
- Kenneth J. Livak,
- Lihua Zou,
- Youzhong Wan,
- Sergej Konoplev,
- Carrie Sougnez,
- Jennifer R. Brown,
- Lynne V. Abruzzo,
- Scott L. Carter,
- Michael J. Keating,
- Matthew S. Davids,
- William G. Wierda,
- Kristian Cibulskis,
- Thorsten Zenz,
- Lillian Werner,
- Paola Dal Cin,
- Peter Kharchencko,
- Donna Neuberg,
- Hagop Kantarjian,
- Eric Lander,
- Stacey Gabriel,
- Susan O’Brien,
- Anthony Letai,
- David A. Weitz,
- Martin A. Nowak,
- Gad Getz,
- Catherine J. Wu
Affiliations
- Jan A. Burger
- Department of Leukemia, MD Anderson Cancer Center
- Dan A. Landau
- Broad Institute
- Amaro Taylor-Weiner
- Broad Institute
- Ivana Bozic
- Department of Mathematics, Program for Evolutionary Dynamics, Harvard University
- Huidan Zhang
- Department of Physics, School of Engineering and Applied Sciences, Harvard University
- Kristopher Sarosiek
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Lili Wang
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Chip Stewart
- Broad Institute
- Jean Fan
- Center for Biomedical Informatics, Harvard Medical School
- Julia Hoellenriegel
- Department of Leukemia, MD Anderson Cancer Center
- Mariela Sivina
- Department of Leukemia, MD Anderson Cancer Center
- Adrian M. Dubuc
- Department of Pathology, Brigham and Women's Hospital and Harvard Medical School
- Cameron Fraser
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Yulong Han
- Bioinspired Engineering and Biomechanics Center, Xi’an Jiaotong University
- Shuqiang Li
- Fluidigm Corporation
- Kenneth J. Livak
- Fluidigm Corporation
- Lihua Zou
- Broad Institute
- Youzhong Wan
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Sergej Konoplev
- Department of Hematopathology, MD Anderson Cancer Center
- Carrie Sougnez
- Broad Institute
- Jennifer R. Brown
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Lynne V. Abruzzo
- Department of Hematopathology, MD Anderson Cancer Center
- Scott L. Carter
- Broad Institute
- Michael J. Keating
- Department of Leukemia, MD Anderson Cancer Center
- Matthew S. Davids
- Department of Medical Oncology, Dana-Farber Cancer Institute
- William G. Wierda
- Department of Leukemia, MD Anderson Cancer Center
- Kristian Cibulskis
- Broad Institute
- Thorsten Zenz
- National Center for Tumors and German Cancer Research Center (DKFZ)
- Lillian Werner
- Biostatistics and Computational Biology, Dana-Farber Cancer Institute
- Paola Dal Cin
- Department of Pathology, Brigham and Women's Hospital and Harvard Medical School
- Peter Kharchencko
- Center for Biomedical Informatics, Harvard Medical School
- Donna Neuberg
- Biostatistics and Computational Biology, Dana-Farber Cancer Institute
- Hagop Kantarjian
- Department of Leukemia, MD Anderson Cancer Center
- Eric Lander
- Broad Institute
- Stacey Gabriel
- Broad Institute
- Susan O’Brien
- Department of Leukemia, MD Anderson Cancer Center
- Anthony Letai
- Department of Medical Oncology, Dana-Farber Cancer Institute
- David A. Weitz
- Department of Physics, School of Engineering and Applied Sciences, Harvard University
- Martin A. Nowak
- Department of Mathematics, Program for Evolutionary Dynamics, Harvard University
- Gad Getz
- Broad Institute
- Catherine J. Wu
- Broad Institute
- DOI
- https://doi.org/10.1038/ncomms11589
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 13
Abstract
The BTK inhibitor ibrutinib is used to treat chronic lymphocytic leukaemia, however some patients develop resistance to the drug. Here, the authors use genomic analyses to examine the clonal evolution of 5 patients that develop resistance to ibrutinib.
